TAS2R38 and COVID-19: Our present findings suggest that subjects with PCD may not be at increased risk of COVID-19 and/or of severe outcomes and that the different haplotypes of the gene codifying for the bitter taste receptor TAS2R38 do not seem to correlate with a propensity to SARS-CoV-2 infection.